Helicobacter pylori antibody responses in association with eradication outcome and recurrence: A population-based intervention trial with 7.3-year follow-up in China

Chinese Journal of Cancer Research

Volumn 29, Issue 2, 2017, Pages 127-136

  Wang, Tianyi ^a   Zhang, Yang ^a   Su, Huijuan ^a   Li, Zhexuan ^a   Zhang, Lian ^a   Ma, Junling ^a   Liu, Weidong ^b   Zhou, Tong ^a   You, Weicheng ^a   Pan, Kaifeng ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b Linqu Public Health Bureau   (China)

Author keywords

Biomarker; Helicobacter pylori; Recurrence; Serology; Treatment outcome

Indexed keywords

AMOXICILLIN; IMMUNOGLOBULIN G; OMEPRAZOLE;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CHINA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERADICATION THERAPY; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEROLOGY; TREATMENT OUTCOME; UREA BREATH TEST;

EID: 85019659116     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.21147/j.issn.1000-9604.2017.02.05     Document Type: Article

References (48)

1. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43.
2. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
3. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J NatI Cancer Inst 2006;98:974-83.
4. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94.
5. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
6. Ley C, Mohar A, Guarner J, et al. Helicobacter pylori eradication and gastric preneoplastic conditions: a randomized, double-blind, placebo-controlled trial. Cancer Epidemiol Biomarkers Prev 2004;13:4-10.
7. IARC Helicobacter pylori Working Group (2014). Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8). Available online: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php
8. van der Hulst RW, Keller JJ, Rauws EA, et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1996;1:6-19.
9. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005;100:2083-99.
10. Pan KF, Zhang L, Gerhard M, et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut 2016;65:9-18.
11. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection — a critical review. Aliment Pharmacol Ther 2004;20:1001-17.
12. Ho B, Marshall BJ. Accurate diagnosis of Helicobacter pylori. Serologic testing. Gastroenterol Clin North Am 2000;29:853-62.
13. Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J NatI Cancer Inst 2012;104:488-92.
14. You WC, Blot WJ, Li JY, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993;53:1317-21.
15. Gail MH, You WC, Chang YS, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials 1998;19:352-69.
16. Jiang J, Wang SZ, Li XM, et al. The modification of 13C-urea breath test. Zhonghua He Yi Xue Zai Zhi (in Chinese) 1994;14:103-5.
17. Zhang L, Blot WJ, You WC, et al. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 1996;5:627-30.
18. Markwell MA, Haas SM, Bieber L, et al. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978;87:206-10.
19. Perez-Perez GI, Dworkin BM, Chodos JE, et al. Campylobacter pylori antibodies in humans. Ann Intern Med 1988;109:11-7.
20. Perez-Perez GI, Marrie T, Inouye H, et al. The effect of age and occupation on the seroprevalence of Helicobacter pylori infection. Can J Infect Dis 1992;3:134-8.
21. Pérez-Pérez GI, Thiberge JM, Labigne A, et al. Relationship of immune response to heat-shock protein A and characteristics of Helicobacter pylori — infected patients. J Infect Dis 1996;174:1046-50.
22. Drumm B, Perez-Perez GI, Blaser MJ, et al. Intrafamilial clustering of Helicobacter pylori infection. N Engl J Med 1990;322:359-63.
23. Glassman MS, Dallal S, Berezin SH, et al. Helicobacter pylori-related gastroduodenal disease in children. Diagnostic utility of enzyme-linked immunosorbent assay. Dig Dis Sci 1990;35:993-7.
24. Groves FD, Zhang L, Li JY, et al. Comparison of two enzyme-linked immunosorbent assay tests for diagnosis of Helicobacter pylori infection in China. Cancer Epidemiol Biomarkers Prev 1997;6:551-2.
25. Formichella L, Romberg L, Bolz C, et al. A novel line immunoassay based on recombinant virulence factors enables highly specific and sensitive serologic diagnosis of Helicobacter pylori infection. Clin Vaccine Immunol 2013;20:1703-10.
26. Nölting C, Reichhuber C, Formichella L, et al. Development and validation of a novel line immunoassay for diagnosis of Helicobacter pylori infection. Z Gastroenterol 2016;54-KV417.
27. Lee JH, Kim N, Chung JI, et al. Long-term Follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea. Helicobacter 2008;13:288-94.
28. Wang WM, Chen CY, Jan CM, et al. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol 1994;89:1793-6.
29. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
30. Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J NatI Cancer Inst 2014;106. Pii:dju116.
31. Suzuki T, Matsuo K, Sawaki A, et al. Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2006;24:273-80.
32. Annibale B, Lahner E, Santucci A, et al. CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis. Helicobacter 2007;12:23-30.
33. Fusconi M, Vaira D, Menegatti M, et al. Anti-CagA Reactivity in Helicobacter pylori-negative subjects: a comparison of three different methods. Dig Dis Sci 1999;44:1691-5.
34. Cai H, Ye F, Michel A, et al. Helicobacter pylori blood biomarker for gastric cancer risk in East Asia. Int J Epidemiol 2016;45:774-81.
35. Eaton KA, Suerbaum S, Josenhans C, et al. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes. Infect Immun 1996;64:2445-8.
36. Khalifeh Gholi M, Kalali B, Formichella L, et al. Helicobacter pylori FliD protein is a highly sensitive and specific marker for serologic diagnosis of H. pylori infection. Int J Med Microbiol 2013;303:618-23.
37. Carlsohn E, Nyström J, Bölin I, et al. HpaA is essential for Helicobacter pylori colonization in mice. Infect Immun 2006;74:920-6.
38. Blom K, Lundin BS, Bölin I, et al. Flow cytometric analysis of the localization of Helicobacter pylori antigens during different growth phases. FEMS Immunol Med Microbiol 2001;30:173-9.
39. Lundström AM, Blom K, Sundaeus V, et al. HpaA shows variable surface localization but the gene expression is similar in different Helicobacter pylori strains. Microb Pathog 2001;31:243-53.
40. O’Toole PW, Janzon L, Doig P, et al. The putative neuraminyllactose-binding hemagglutinin HpaA of Helicobacter pylori CCUG 17874 is a lipoprotein. J Bacteriol 1995;177:6049-57.
41. Voland P, Hafsi N, Zeitner M, et al. Antigenic properties of HpaA and Omp18, two outer membrane proteins of Helicobacter pylori. Infect Immun 2003;71:3837-43.
42. Pan KF, Formichella L, Zhang L, et al. Helicobacter pylori antibody responses and evolution of precancerous gastric lesions in a Chinese population. Int J Cancer 2014;134:2118-25.
43. Gao L, Michel A, Weck MN, et al. Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res 2009;69:6164-70.
44. Epplein M, Zheng W, Xiang YB, et al. Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. Cancer Epidemiol Biomarkers Prev 2012;21:2185-92.
45. Formichella L, Göttner G, Nölting C, et al. Correlation of IgG immune responses to selected H. pylori proteins with disease status in different populations. Poster presented at the XXVIIth International Workshop of the European Helicobacter Study Group (2014).
46. Formichella L, Romberg L, Vieht M, et al. Evaluation of IgG immune responses to 15 H. pylori proteins. Poster presented at the XXVIth International Workshop of the European Helicobacter Study Group (2013).
47. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-5.
48. Basso D, Navaglia F, Brigato L, et al. Analysis of Helicobacter pylori vacA and cagA genotypes and serum antibody profile in benign and malignant gastroduodenal diseases. Gut 1998;43:182-6.